Metraipolis › archive › dc_8934cc690bf8

Risk of severe infections in patients with triple-negative breast cancer treated with atezolizumab plus nab-paclitaxel: a real-world, postmarketing database… — Europe PMC PMID:41162823

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41162823
DOI
10.1007/s10147-[numero omesso]-0
License (as archived)
solo-consultazione
Archived
2026-11-08T22:44:17.827Z
SHA-256 of the archived text
9b2aa3eec1a07bacb668ab92c1b483247266998b004f651d75a88f6639e858ab
Stable URL of this page
https://metraipolis.com/documento/dc_8934cc690bf8

How to cite

Risk of severe infections in patients with triple-negative breast cancer treated with atezolizumab plus nab-paclitaxel: a real-world, postmarketing database… — Europe PMC PMID:41162823 — Europe PMC (en), https://europepmc.org/article/MED/41162823 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_8934cc690bf8 (Metraipolis archive dc_8934cc690bf8, sha256 9b2aa3eec1a07bacb668ab92c1b483247266998b004f651d75a88f6639e858ab)
BibTeX
@misc{dc8934cc690bf8,
  title = {Risk of severe infections in patients with triple-negative breast cancer treated with atezolizumab plus nab-paclitaxel: a real-world, postmarketing database… — Europe PMC PMID:41162823},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41162823},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_8934cc690bf8; sha256 9b2aa3eec1a07bacb668ab92c1b483247266998b004f651d75a88f6639e858ab},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41162823. Agents can read the archived copy with the MCP tool read_document.